• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
By JIM CRAMER
Aug 21, 2018 | 06:44 AM EDT
Stocks quotes in this article: JNJ, PFE, MRK, AEP, AGN

We don't know what it says when we see Johnson & Johnson's (JNJ) stock go for a spurt on no news. We are mystified by the runs in Merck  (MRK) and Pfizer (PFE) , because they are based on nothing happening at the companies. We could find individual drug approvals and point to them as catalysts: heaven knows all three, JNJ. MRK and PFE, have them regularly. But, when I peruse the news wires, there's no drug approvals of any consequence.

Still, the one thing we know to be the case? Only a recession would give you a rally of this magnitude. These stocks are predicting a recession, plain and simple. I don't believe it, but that's what they have always stood for.

I could say the exact same thing about the utilities. I had American Electric Power (AEP) , the biggest transmission company in our country, on last week, and while I would like to say that its stock just jumped ten points because of its excellent cost controls and above average customer payments because of renewed demand, all I can really point to is that rates have come down on the 10-year, and that drives this stock and its cohort higher. Recession.

Oh, and heaven knows why the consumer-packaged goods stocks are going higher, at least the ones with decent yields. They typically flag a recession, too.

And let's throw in the real estate investment trusts of all kinds. Their lift-off normally would signal some sort of recession on the horizon -- because of their higher-than-average yield, which won't be available from bonds.

But I think these stocks have all lost their predictive behavior. Sure, they are captured by the 10-year. However, I now think that this is simply rotational behavior 2018-style and it requires all new rules to live by.

First, I would say that there is an obvious correlation between the 10-year and these stocks. When rates are headed from 3% down to 2.5%, they are buys. When they are headed from 2.5% to 3%, they are sales.

We are in buy mode.

Second, these stocks no longer seem to correlate with the economy all that much, at least not any more than the 10-year, which seems to correlate with, well, nothing.

I think they really correlate with the flow of funds in the market. When we worry about world trade slowing, we do buy staples, including big pharma -- not biotech but big pharma. It is possible if the trade war picks up that worldwide growth will slow. But I think that the rally in the drug stocks is really about institutions being underweight a terrific group. Pfizer has outlined plans for a possible break-up.

Merck has Keytruda, which is a keystone anti-cancer drug. Johnson & Johnson has some fabulous potential blockbusters that aren't in the stock yet. Investors want stocks that haven't really moved that have the potential for good news. Consider that Allergan (AGN) , the most despised drug company at one point, has now gone from $144 in May to $190, with scarcely a single important announcement. I do think some could be on the horizon, though, or I wouldn't have liked it in the first place.

As far as the REITs: Sure, the retail REITs are better because of a cessation in bankruptcies. But the rest of the rally? I think it is ETF money in search of yield while real estate, including the malls, have, surprisingly, held up in value as the worst fears have not been realized.

So, rant and rave that this whole move has to be saying a recession is beckoning. To me, employment, retail sales, confidence -- they are all so high that a recessionary view seems fanciful even with all of the potential tariffs being thrown around.

I always want to be cautious on these moves. The action in these identical stocks from back in 2000 influences my thinking. They rallied and a recession was right over the hill they had just climbed.

This time? It's different. There's no recession; there's simply a rotation from one group that got expensive to another group that is cheap, no more than that. There's too much evidence of strength -- job growth, small business confidence, car loadings -- and if you overthink it and interpret these moves as a sign of a real slowdown, I believe you will cost yourself a lot of the money that you should be making if you weren't betting that the economy's about to roll over.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Action Alerts PLUS, which Cramer co-manages as a charitable trust, has no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare | Basic Materials | ETFs | Funds | Markets | Stocks | Economy

More from Healthcare

I'm Buying Arcturus Therapeutics Stock and Here's the Reason Why

Jim Collins
Apr 5, 2021 10:15 AM EDT

My COVID vaccine eligibility actually began about a week before my symptoms began.

Gilead Sciences Quant Upgrade Got Me Thinking

Bruce Kamich
Mar 31, 2021 1:55 PM EDT

The upgrade got my attention, but positive-looking charts pushed me over the edge.

Jim Cramer: For This Pandemic, and the Next, There Are Several Stocks I Like Now

Jim Cramer
Mar 31, 2021 7:01 AM EDT

There's an undercurrent that will grow over time, basically what tailwinds from the pandemic will stay with us after the pandemic's over.

The Doctor Found Something Amiss on the Charts of Teladoc

Bruce Kamich
Mar 30, 2021 2:27 PM EDT

The name appears bearish and risky right now.

Here's Why I'm Avoiding AstraZeneca Stock

Jim Collins
Mar 25, 2021 10:00 AM EDT

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login